SIMULTANEOUS ESTIMATION OF MOXIFLOXACIN HCl AND BROMFENAC SODIUM IN EYE DROPS BY SPECTROPHOTOMETRIC METHODS

Moxifloxacin Hydrochloride is a fluorinated quinolone antibacterial and Bromfenac Sodium is a non-steroidal anti-inflammatory. The combination formulation is used for the treatment of the reduction of post operative inflammatory conditions of the eye. Three new, simple, accurate and precise UV spectrophotometric methods have been developed and validated for the simultaneous determination of Moxifloxacin Hydrochloride (MOX) and Bromfenac Sodium (BROM) in their combined dosage forms. Method – I is based on simultaneous equation method using two wavelengths, 294 nm (λmax of MOX) and 265 nm (λmax of BROM). Method – II Q‐absorption Ratio method using two wavelengths, 294 nm (λmax of MOX) and 276.66 nm (Isoabsorptive point). Method – III involves the use of First order derivative technique. Here 301.71 nm, the zero crossing point of Bromfenac Sodium, was selected for the determination of Moxifloxacin Hydrochloride and 293.22 nm, the zero crossing point of Moxifloxacin Hydrochloride, was selected for the determination of Bromfenac Sodium. Methanolic HCL (0.1 M) was the solvent used in all three methods. Moxifloxacin showed linearity in the range of 1-14 μg/ml and Bromfenac showed linearity in the range of 1-14 μg/ml in all the methods. All methods were validated statistically and recovery studies were carried out. All methods were found to be accurate, precise and reproducible. These methods were applied to the assay of the drugs in marketed formulation, which were found in the range of 98.0% to 102.0% of the labelled value for both Moxifloxacin and Bromfenac. Hence, the methods herein described can be successfully applied in quality control of combined pharmaceutical dosage forms.